Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for 60 Degrees Pharmaceuticals Inc. (SXTP : NSDQ)
 
 • Company Description   
60 Degrees Pharmaceuticals Inc. specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. 60 Degrees Pharmaceuticals Inc. is based in WASHINGTON.

Number of Employees: 3

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.61 Daily Weekly Monthly
20 Day Moving Average: 77,935 shares
Shares Outstanding: 1.47 (millions)
Market Capitalization: $3.84 (millions)
Beta: 2.78
52 Week High: $16.26
52 Week Low: $1.41
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 14.47% 10.19%
12 Week -17.41% -30.53%
Year To Date -59.53% -62.10%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1025 CONNECTICUT AVENUE NW SUITE 1000
-
WASHINGTON D.C.,WA 20036
USA
ph: 202-327-5422
fax: -
ir@60degreespharma.com http://www.60degreespharma.com
 
 • General Corporate Information   
Officers
Geoffrey Dow - Chief Executive Officer; President and Director
Tyrone Miller - Chief Financial Officer
Kristen Landon - Chief Commercial Officer
Charles Allen - Director
Cheryl Xu - Director

Peer Information
60 Degrees Pharmaceuticals Inc. (GSAC)
60 Degrees Pharmaceuticals Inc. (CASI)
60 Degrees Pharmaceuticals Inc. (ALCD.)
60 Degrees Pharmaceuticals Inc. (OMNN)
60 Degrees Pharmaceuticals Inc. (CGPI.)
60 Degrees Pharmaceuticals Inc. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 83006G401
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/13/25
Share - Related Items
Shares Outstanding: 1.47
Most Recent Split Date: 2.00 (0.20:1)
Beta: 2.78
Market Capitalization: $3.84 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.21 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.92 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 7.30
EPS Growth
vs. Year Ago Period: -186.63%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: 125.93%
vs. Previous Quarter: -32.69%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -174.90
12/31/24 - -122.89
Current Ratio
06/30/25 - -
03/31/25 - 3.14
12/31/24 - 3.25
Quick Ratio
06/30/25 - -
03/31/25 - 2.71
12/31/24 - 2.98
Operating Margin
06/30/25 - -
03/31/25 - -1,949.01
12/31/24 - -1,871.81
Net Margin
06/30/25 - -
03/31/25 - -1,947.30
12/31/24 - -1,869.22
Pre-Tax Margin
06/30/25 - -
03/31/25 - -1,947.30
12/31/24 - -1,168.14
Book Value
06/30/25 - -
03/31/25 - -3.76
12/31/24 - -6.38
Inventory Turnover
06/30/25 - -
03/31/25 - 0.75
12/31/24 - 0.88
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©